May 4, 2011 – Researchers from the University of Cincinnati presented results from a prospective study at the American Roentgen Ray Society 2011 annual meeting this week, demonstrating how positron emission mammography (PEM)-guided biopsy may expedite pre-operative work-up and reduce radiation exposure for breast cancer patients.

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment. Naviscan’s Stereo Navigator Accessory is the first commercialized PET-guided biopsy tool and has been U.S. Food and Drug Administration (FDA)-cleared since 2008.

"PEM is useful for performing local staging in women with newly diagnosed breast cancer,” said Amy Argus, M.D., assistant professor of radiology and one of the lead investigators of the study. “When additional breast abnormalities are identified by PEM, accurate PEM-guided biopsy can be performed on the same day as the diagnostic imaging, which decreases the patient's radiation dose and may expedite their preoperative work-up."

In this study, 18 women with breast cancer classified as BIRADS 5 identified on mammography or ultrasound underwent a PEM scan and same day PEM-guided biopsy on 24 index and satellite lesions. Lesion size was 4-60 mm with a mean size of 16 mm. Results were concordant for 83 percent of lesions and discordant for the remaining due to patient movement and operator experience. PEM is the only technology where physicians are able to biopsy on the same injection of the radiotracer. This is because the radiotracer utilized, FDG, does not washout of the tumor as with other blood flow-dependant modalities like MRI or BSGI. By avoiding a double injection of radiotracer, the radiation exposure to the patient and medical personnel is reduced. Same day procedures are also feasible with PEM given the ease of interpretation compared to other advanced imaging modalities.

For more information: www.naviscan.com


Related Content

News | Breast Imaging

July 29, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time July 29, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
Videos | Breast Imaging

Don't miss ITN's latest "One on One" video interview with AAWR Past President and American College of Radiology (ACR) ...

Time July 24, 2024
arrow
News | Flat Panel Displays

July 17, 2024 — LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic ...

Time July 17, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Artificial Intelligence

July 9, 2024 — Lunit, a provider of Artificial Intelligence (AI)-powered solutions for cancer diagnostics and ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Artificial Intelligence

June 26, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced it ...

Time June 26, 2024
arrow
News | Breast Imaging

June 20, 2024 — The technologically advanced VELA Mammography Chair, offered by Enable Me, a VELA Medical company ...

Time June 20, 2024
arrow
News | Nuclear Imaging

June 20, 2024 — GE HealthCare joined the world’s top medical and academic institutions at the Society of Nuclear ...

Time June 20, 2024
arrow
Subscribe Now